 Xanthine Oxidase
"Xanthine Oxidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An iron-molybdenum flavoprotein containing FLAVIN-ADENINE DINUCLEOTIDE that oxidizes hypoxanthine, some other purines and pterins, and aldehydes. Deficiency of the enzyme, an autosomal recessive trait, causes xanthinuria.
| Descriptor ID |
D014969
|
| MeSH Number(s) |
D08.811.682.047.928
|
| Concept/Terms |
Xanthine Oxidase- Xanthine Oxidase
- Oxidase, Xanthine
- Hypoxanthine Oxidase
- Oxidase, Hypoxanthine
- Purine-Xanthine Oxidase
- Oxidase, Purine-Xanthine
- Purine Xanthine Oxidase
- Hypoxanthine Dehydrogenase
- Dehydrogenase, Hypoxanthine
- Hypoxanthine-Xanthine Oxidase
- Hypoxanthine Xanthine Oxidase
- Oxidase, Hypoxanthine-Xanthine
|
Below are MeSH descriptors whose meaning is more general than "Xanthine Oxidase".
Below are MeSH descriptors whose meaning is more specific than "Xanthine Oxidase".
This graph shows the total number of publications written about "Xanthine Oxidase" by people in this website by year, and whether "Xanthine Oxidase" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 | | 2000 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 1 | 1 | 2 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2008 | 1 | 1 | 2 | | 2010 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Xanthine Oxidase" by people in Profiles.
-
Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, Hein DW, van der Horst C, Kashuba AD. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol. 2010 May; 66(5):475-85.
-
Kennedy MJ, Davis DA, Smith N, Gaedigk A, Pearce RE, Kearns GL. Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency. Clin Pharmacol Ther. 2008 Dec; 84(6):674-8.
-
Kennedy MJ, Davis DA, Smith N, Gaedigk A, Pearce RE, Kearns GL. Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement. Clin Ther. 2008 Sep; 30(9):1687-99.
-
Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006 Apr; 50(4):1130-5.
-
Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, Gaedigk A, Bertino JS. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol. 2005 Dec; 45(12):1413-21.
-
Kennedy MJ, Abdel-Rahman SM, Kashuba AD, Leeder JS. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol. 2004 Jul; 44(7):708-14.
-
Kennedy MJ, Scripture CD, Kashuba AD, Scott CS, Gaedigk A, Kearns GL. Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis. Clin Pharmacol Ther. 2004 Mar; 75(3):163-71.
-
Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 2003 Nov; 74(5):437-47.
-
Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther. 2000 Oct; 68(4):375-83.
-
Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998 Sep; 64(3):257-68.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|